Drug Trial News

RSS

Oral PCSK9-inhibitor highly effective at reducing high levels of LDL cholesterol, studies show

Results from two early clinical studies show the first version of an oral PCSK9-inhibitor cholesterol-lowering medicine was well tolerated and highly effective at reducing high levels of LDL cholesterol, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2021.

15 Nov 2021

Prescription omega-3 pill did not reduce hospitalization or death from COVID-19

A high dose of a purified omega-3 fatty acid, available by prescription only, was well tolerated; however, it did not substantially reduce incidents of hospitalizations and/or deaths among people with COVID-19, according to a late-breaking clinical trial presented today at the American Heart Association's Scientific Sessions 2021.

15 Nov 2021

Analysis of immunodeficient patients granted REGEN-COV under compassionate use COVID-19 program

A team of scientists describe the safety and response to REGEN-COV® for COVID-19 patients with immunodeficiency-associated antibody disorders.

11 Nov 2021

Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds

A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.

11 Nov 2021

University of Oxford begins Phase I trial to test Ebola vaccine

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers - with the first vaccinations taking place today (Thursday, 11 November).

11 Nov 2021

Effectiveness of sotrovimab demonstrated in patients with mild to moderate COVID-19

In an attempt to study the safety and effectiveness of sotrovimab in more vulnerable patients suffering from mild to moderate symptoms of COVID-19, a multinational team of researchers conducted the COVID-19 Monoclonal antibody Efficacy Trial-Intent to Care Early (COMET-ICE) trial.

11 Nov 2021

REGEN-COV shown to rapidly reduce SARS-CoV-2 viral load in hospitalized COVID-19 patients

Studies have shown that mortality rates in hospitalized patients with COVID-19 are high, ranging between 10% and 30%. REGEN-COV®, a combination of monoclonal antibodies casirivimab and imdevimab, is approved in the United States and other regions for emergency treatment of COVID-19 outpatients with mild to moderate SARS-CoV-2 infection and post-exposure prophylaxis.

10 Nov 2021

Immune checkpoint inhibitor therapy results in longer treatment-free survival for patients with advanced renal cell carcinoma

Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial.

10 Nov 2021

ACTG announces launch of clinical trial evaluating a three-month TB treatment

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB).

10 Nov 2021

Stenoparib effectively inhibits SARS-CoV-2 variants in vitro

A new study assesses the antiviral activity of stenoparib against four SARS-CoV-2 strains.

10 Nov 2021

A measles-vectored COVID-19 vaccine induces strong immunity in animal model

A new study explores the potential of MV-based vaccines targeting the S protein of SARS-CoV-2.

9 Nov 2021

International Alzheimer’s trial to evaluate a combination of drugs targeting two brain proteins

Trial participant Rachel Habiger meets in 2018 with Randall J. Bateman, MD, the director of the Dominantly Inherited Alzheimer Network Trials Unit at Washington University School of Medicine in St. Louis.

8 Nov 2021

Discovery of potent neutralizing antibodies against SARS-CoV-2 variants

In a recent study, the researchers identify and characterize mAbs that are effective against the wild-type SARS-CoV-2 strain and B.1.351 variant.

8 Nov 2021

Study compares efficacy of BNT162b2 and CoronaVac as the booster dose for COVID-19 vaccination

A recent study reports the immunogenicity and safety of BNT162b2 and CoronaVac as the third dose in CoronaVac-immunized adults.

8 Nov 2021

Rapid antibody response induced by mRNA COVID vaccines in mice

A new study posted in the bioRxiv* preprint server used mouse models to investigate how mRNA vaccines elicit a rapid antibody response. Their findings show two different mRNA vaccines successfully boost antibody levels — IL-5, IL-6, and MCP-1 —5 days after administration.

7 Nov 2021

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

A new study describes a new small molecule compound that has shown impressive safety, tolerability, and bioavailability against SARS-CoV-2.

7 Nov 2021

Diabetes medication reduces the rate of kidney function decline in CKD patients

Clinical trial data reveal that dapagliflozin-; a sodium-glucose cotransporter 2 inhibitor prescribed to treat diabetes-;reduces the rate of kidney function decline in patients with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Oral drug works just as well as conventional therapy for anemia in patients with kidney disease

Anemia is a common and sometimes debilitating problem among patients with chronic kidney disease (CKD). Anemia can occur when the kidneys become damaged, limiting the production of erythropoietin (EPO) -; a hormone that signals to the body to make red blood cells.

7 Nov 2021

Investigation of Budesonide's mechanism of action against SARS-CoV-2

Researchers look to gain an understanding of the mechanism of action of budesonide in improving the prognosis of patients with SARS-CoV-2 infection.

1 Nov 2021

Largest real-world study evaluates the effectiveness of third "booster" dose of COVID-19 vaccine

The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the effectiveness of the third dose of the Pfizer/BioNTech BNT162B2 vaccine against the Delta variant of SARS-CoV-2.

30 Oct 2021

Previous
1
...
41
42
43
44
45
46
47
...
1143
Next

Drug Trial News

Oral PCSK9-inhibitor highly effective at reducing high levels of LDL cholesterol, studies show

Prescription omega-3 pill did not reduce hospitalization or death from COVID-19

Analysis of immunodeficient patients granted REGEN-COV under compassionate use COVID-19 program

Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds

University of Oxford begins Phase I trial to test Ebola vaccine

Effectiveness of sotrovimab demonstrated in patients with mild to moderate COVID-19

REGEN-COV shown to rapidly reduce SARS-CoV-2 viral load in hospitalized COVID-19 patients

Immune checkpoint inhibitor therapy results in longer treatment-free survival for patients with advanced renal cell carcinoma

ACTG announces launch of clinical trial evaluating a three-month TB treatment

Stenoparib effectively inhibits SARS-CoV-2 variants in vitro

A measles-vectored COVID-19 vaccine induces strong immunity in animal model

International Alzheimer’s trial to evaluate a combination of drugs targeting two brain proteins

Discovery of potent neutralizing antibodies against SARS-CoV-2 variants

Study compares efficacy of BNT162b2 and CoronaVac as the booster dose for COVID-19 vaccination

Rapid antibody response induced by mRNA COVID vaccines in mice

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

Diabetes medication reduces the rate of kidney function decline in CKD patients

Oral drug works just as well as conventional therapy for anemia in patients with kidney disease

Investigation of Budesonide's mechanism of action against SARS-CoV-2

Largest real-world study evaluates the effectiveness of third "booster" dose of COVID-19 vaccine

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News